Posted by Michael Wonder on 27 Apr 2020
Eiger BioPharmaceuticals announces EMA validation of lonafarnib MAA for treatment of progeria and progeroid laminopathies
27 April 2020 - Accelerated assessment of application previously granted by EMA in March.
Eiger BioPharmaceuticals today announced that the EMA has completed its validation of the marketing authorisation application (MAA) for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies.
Validation of the application confirms that the submission is accepted and starts the formal review process by the EMA’s Committee for Human Medicinal Products.
